1. Home
  2. SCKT vs CVKD Comparison

SCKT vs CVKD Comparison

Compare SCKT & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Socket Mobile Inc.

SCKT

Socket Mobile Inc.

HOLD

Current Price

$0.51

Market Cap

3.4M

Sector

Technology

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$1.07

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCKT
CVKD
Founded
1992
2022
Country
United States
United States
Employees
N/A
5
Industry
Computer Manufacturing
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
4.0M
IPO Year
1996
2022

Fundamental Metrics

Financial Performance
Metric
SCKT
CVKD
Price
$0.51
$1.07
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
166.0K
1.2M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.94
EPS
N/A
N/A
Revenue
$15,078,332.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.38
$1.00
52 Week High
$2.79
$14.64

Technical Indicators

Market Signals
Indicator
SCKT
CVKD
Relative Strength Index (RSI) 43.80 26.67
Support Level $0.38 $1.00
Resistance Level $0.99 $2.23
Average True Range (ATR) 0.04 0.11
MACD -0.01 0.01
Stochastic Oscillator 26.53 12.09

Price Performance

Historical Comparison
SCKT
CVKD

About SCKT Socket Mobile Inc.

Socket Mobile Inc is a producer of data capture products. The company's products are integrated into mobile applications used in mobile point of sale (mPOS), commercial services (field workers), asset tracking, manufacturing process and quality control, transportation and logistics (goods tracking and movement), event management (ticketing, entry, access control, and identification), medical and education. The company offers barcode scanning products for both one-dimensional, including imager and laser, and two-dimensional barcode scanning in standard and durable cases. The company's geographical segments are the United States, Europe, Asia and Rest of the world, of which the majority of the revenue is generated from the United States.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: